Midazolam is a short-acting benzodiazepine used in neonatal intensive care units for
sedation. Reports from Europe have described adverse neurological effects in infants …

Children are not small adults because besides size there are subtle physiological and
biochemical differences between children and adults. Like adults, children also require …

Background: Physiological‐based pharmacokinetic models have been used to describe
midazolam clearance (CL) maturation. There are no maturation descriptors of CL from …

Results The nasal route was well accepted by 59% of patients in group A, 62% of group B
and 97% of group C. Statistical analysis using Kruskall Wallis test showed significant …

One hundred children aged between 6 months and 10 years undergoing elective urological
surgery, received 0.4 mg/kg midazolam orally about 20 minutes prior to the arrival in the …

Results: In Group O and IN, 15/30 children (50%) and 7/30 children (23%) accepted drug
easily (P< 0.05); 4/22 children (18%) in Group O and 11/20 children (55%) in Group IN cried …

In France, the legal routes used to administer midazolam to a patient are intravenously and
intramuscularly. For anaesthetists, these routes are not well adapted to paediatric use; they …

Introduction In the absence of a licensed formulation in many countries worldwide,
ADV6209, an innovative 2 mg/ml oral solution of midazolam containing cyclodextrin, has …

Introduction Operation theatre environment, surgery and anaesthesia cause stress and
anxiety which can induce psychological disturbances in children. Sedative anxiolytic …

Twelve children 1-5 y old were randomly assigned to receive midazolam 0.2 mg. kg-1 either
by the intravenous (IV) or intranasal (IN) routes. After IN administration the rapid onset of …